Cardiology Research and Practice最新文献

{"title":"The Impact of Complete Revascularization in Symptomatic Severe Left Ventricular Dysfunction between Coronary Artery Bypass Graft and Percutaneous Coronary Intervention.","authors":"Hsiu-Yu Fang, Yen-Nan Fang, Yin-Chia Chen, Jiunn-Jye Sheu, Wei-Chieh Lee","doi":"10.1155/2023/9226722","DOIUrl":"10.1155/2023/9226722","url":null,"abstract":"<p><strong>Objective: </strong>The study aimed to compare the clinical outcomes between the patients receiving coronary artery bypass surgery (CABG) or percutaneous coronary intervention (PCI) for the patients with symptomatic severe left ventricular (LV) dysfunction and coronary artery disease (CAD).</p><p><strong>Methods: </strong>Between February 2007 and February 2020, a total of 745 patients who received coronary artery angiography for reduced LV ejection fraction (LVEF) < 40% and symptomatic New York Heart Association (NYHA) functional class ≥ 3 were recruited. The patients (<i>N</i> = 236) who were diagnosed with dilated cardiomyopathy or valvular heart disease without coronary artery stenosis, those with prior history of CABG or valvular surgery (<i>N</i> = 59), those who presented ST-segment elevated myocardial infarction (STEMI), those with a CAD and SYNTAX score of  ≦ 22 (<i>N</i> = 175), those who received emergent CABG for coronary perforation (<i>N</i> = 3), and those who had NYHA class ≦ 2 (<i>N</i> = 65) were excluded. Finally, 116 patients with reduced LVEF and those who had a SYNTAX score >22, who received CABG (N = 47) and PCI (N = 69), were recruited for this study.</p><p><strong>Results: </strong>There was no significant difference in the incidence values of in-hospital course and those of in-hospital mortality, acute kidney injury, and postprocedural hemodialysis. There was no significant difference in the 1-yearfollow-up of recurrent MI, revascularization, or stroke between the groups. The 1-year heart failure (HF) hospitalization rate was significantly lower in the CABG group than in all patients of the PCI group (13.2% vs. 33.3%; <i>p</i> = 0.035); however, there was no significant difference in the same variable between the CABG group and the complete revascularization subgroup (13.2% vs. 28.2%; <i>p</i> = 0.160). The revascularization index (RI) was significantly higher in the CABG group than in all patients of the PCI group or complete revascularization subgroup (0.93 ± 0.12 vs. 0.71 ± 0.25; <i>p</i> < 0.001) and (0.93 ± 0.12 vs. 0.86 ± 0.13; <i>p</i> = 0.019). The 3-year HF hospitalization rate was significantly lower in the CABG group than in all patients of the PCI group (16.2% vs. 42.2%; <i>p</i> = 0.008); however, there was no difference in the same variable between the CABG group and the complete revascularization subgroup (16.2% vs. 35.1%; <i>p</i> = 0.109).</p><p><strong>Conclusions: </strong>In patients with symptomatic (NYHA class ≥ 3) severe LV dysfunction and CAD, CABG brought less HF admission when compared to patients in the PCI group, but this did not differ when compared to the complete revascularization subgroup. Therefore, an extensive revascularization, achieved by CABG or PCI, is associated with a lower HF hospitalization rate during the 3-yearfollow-up period in such populations.</p>","PeriodicalId":9494,"journal":{"name":"Cardiology Research and Practice","volume":"2023 ","pages":"9226722"},"PeriodicalIF":1.8,"publicationDate":"2023-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9991473/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9088065","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Quantifying Myocardial Blood Flow and Resistance Using 4D-Flow Cardiac Magnetic Resonance Imaging.","authors":"Rebecca C Gosling, Gareth Williams, Abdulaziz Al Baraikan, Samer Alabed, Eylem Levelt, Amrit Chowdhary, Peter P Swoboda, Ian Halliday, D Rodney Hose, Julian P Gunn, John P Greenwood, Sven Plein, Andrew J Swift, James M Wild, Pankaj Garg, Paul D Morris","doi":"10.1155/2023/3875924","DOIUrl":"10.1155/2023/3875924","url":null,"abstract":"<p><strong>Background: </strong>Ischaemia with nonobstructive coronary arteries is most commonly caused by coronary microvascular dysfunction but remains difficult to diagnose without invasive testing. Myocardial blood flow (MBF) can be quantified noninvasively on stress perfusion cardiac magnetic resonance (CMR) or positron emission tomography but neither is routinely used in clinical practice due to practical and technical constraints. Quantification of coronary sinus (CS) flow may represent a simpler method for CMR MBF quantification. 4D flow CMR offers comprehensive intracardiac and transvalvular flow quantification. However, it is feasibility to quantify MBF remains unknown.</p><p><strong>Methods: </strong>Patients with acute myocardial infarction (MI) and healthy volunteers underwent CMR. The CS contours were traced from the 2-chamber view. A reformatted phase contrast plane was generated through the CS, and flow was quantified using 4D flow CMR over the cardiac cycle and normalised for myocardial mass. MBF and resistance (MyoR) was determined in ten healthy volunteers, ten patients with myocardial infarction (MI) without microvascular obstruction (MVO), and ten with known MVO.</p><p><strong>Results: </strong>MBF was quantified in all 30 subjects. MBF was highest in healthy controls (123.8 ± 48.4 mL/min), significantly lower in those with MI (85.7 ± 30.5 mL/min), and even lower in those with MI and MVO (67.9 ± 29.2 mL/min/) (<i>P</i> < 0.01 for both differences). Compared with healthy controls, MyoR was higher in those with MI and even higher in those with MI and MVO (0.79 (±0.35) versus 1.10 (±0.50) versus 1.50 (±0.69), <i>P</i>=0.02).</p><p><strong>Conclusions: </strong>MBF and MyoR can be quantified from 4D flow CMR. Resting MBF was reduced in patients with MI and MVO.</p>","PeriodicalId":9494,"journal":{"name":"Cardiology Research and Practice","volume":"2023 ","pages":"3875924"},"PeriodicalIF":1.8,"publicationDate":"2023-02-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9911256/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9112443","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Plasma Levels of Matrix Metalloproteinases 2 and 9 in Patients with Chronic Chagas Heart Disease and Systemic Arterial Hypertension: Correlation with TGF-Beta Plasma Levels.","authors":"Reinaldo B Bestetti,&nbsp;Renata Dellalibera-Joviliano,&nbsp;Ellen Rizzi,&nbsp;Giselle F Bonacio,&nbsp;Milton Faria-Jr,&nbsp;Rosemeire Furlan-Daniel,&nbsp;Suzeley Castro-França","doi":"10.1155/2023/8484697","DOIUrl":"https://doi.org/10.1155/2023/8484697","url":null,"abstract":"<p><strong>Background: </strong>Chronic Chagas heart disease (CCHD) and systemic arterial hypertension (SAH) frequently coexists in areas where Chagas disease is endemic. The effects of the association of both conditions (CCHD-SAH) on the extracellular matrix (ECM) remodeling are unknown. Matrix metalloproteinases (MMP) 2 and 9 are involved in ECM remodeling. The aim of this study was to evaluate MMP 2 and MMP9 in CCHD-SAH patients and to correlate their levels with those of the profibrogenic cytokine TGF-beta.</p><p><strong>Methods: </strong>We included 19 patients with CCHD-SAH, 14 patients with CCHD alone, and 19 controls matched by sex and age. MMP-2 and MMP-9 plasma levels were studied by gel zymography and showed as optical densities (OD). TGF-beta plasma levels were measured by double-ligand ELISA and expressed as pg/mL.</p><p><strong>Results: </strong>Median (5^th, 95^th) MMP-2 plasma levels were 1224.7 OD (1160, 1433.5) in patients with CCHD alone, 1424.1 OD (1267.5, 1561) in patients with CCHD-SAH, and 940 OD (898.1, 1000.8) in controls (<i>p</i>=0.001). MMP-9 plasma levels were 1870 OD (1740, 1904.1) in patients with CCHD alone, 1754.6 OD (1650, 2049) in those with CCHD-SAH and 89.7 OD (80, 96) in controls (<i>p</i>=0.0003). MMP-9 plasma levels were higher than those of MMP 2 in patients with CCHD-SAH (<i>p</i>=0.01). No correlation was found between TGF-beta plasma levels with MMP-2 serum levels (<i>r</i> = 0.12; <i>p</i>=0.7), but a moderate negative correlation (<i>r</i> = -0.46; <i>p</i>=0.048) was observed between TGF-beta and MMP-9 plasma levels.</p><p><strong>Conclusions: </strong>MMP-2 and especially MMP-9 may play a role in the ECM remodeling process in patients with CCHD-SAH. TGF-Beta may counteract the MMP effect on the ECM remodeling process in patients with CCHD-SAH.</p>","PeriodicalId":9494,"journal":{"name":"Cardiology Research and Practice","volume":"2023 ","pages":"8484697"},"PeriodicalIF":2.1,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10132902/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9393069","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Retracted: Clinical Study on Long-Term Sinus Reversion Rate and Left Atrial Function Recovery of Mitral Valve Disease with Atrial Fibrillation under Modified Surgical Radiofrequency Ablation.","authors":"Cardiology Research And Practice","doi":"10.1155/2023/9820581","DOIUrl":"https://doi.org/10.1155/2023/9820581","url":null,"abstract":"<p><p>[This retracts the article DOI: 10.1155/2021/5667364.].</p>","PeriodicalId":9494,"journal":{"name":"Cardiology Research and Practice","volume":"2023 ","pages":"9820581"},"PeriodicalIF":2.1,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10447015/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10061872","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-World Experience with Cangrelor as Adjuvant to Percutaneous Coronary Intervention: A Single-Centre Observational Study.","authors":"Troels Thim,&nbsp;Lars Jakobsen,&nbsp;Rebekka Vibjerg Jensen,&nbsp;Nicolaj Støttrup,&nbsp;Ashkan Eftekhari,&nbsp;Erik Lerkevang Grove,&nbsp;Sanne Bøjet Larsen,&nbsp;Jacob Thorsted Sørensen,&nbsp;Steen Carstensen,&nbsp;Sahar Amiri,&nbsp;Karsten Tange Veien,&nbsp;Evald Høj Christiansen,&nbsp;Christian Juhl Terkelsen,&nbsp;Michael Maeng,&nbsp;Steen Dalby Kristensen","doi":"10.1155/2023/3197512","DOIUrl":"https://doi.org/10.1155/2023/3197512","url":null,"abstract":"<p><strong>Background: </strong>Reversible P2Y12 inhibition can be obtained with cangrelor administered intravenously. More experience with cangrelor use in acute PCI with unknown bleeding risk is needed.</p><p><strong>Objectives: </strong>To describe real-world use of cangrelor including patient and procedure characteristics and patient outcomes.</p><p><strong>Methods: </strong>We performed a single-centre, retrospective, and observational study including all patients treated with cangrelor in relation to percutaneous coronary intervention at Aarhus University Hospital during the years 2016, 2017, and 2018. We recorded procedure indication and priority, the indications for cangrelor use, and patient outcomes within the first 48 hours after initiation of cangrelor treatment.</p><p><strong>Results: </strong>We treated 991 patients with cangrelor in the study period. Of these, 869 (87.7%) had an acute procedure priority. Among acute procedures, patients were mainly treated for STEMI (<i>n</i> = 723) and the remaining were treated for cardiac arrest and acute heart failure. Use of oral P2Y12 inhibitors prior to percutaneous coronary intervention was rare. Fatal bleeding events (<i>n</i> = 6) were only observed among patients undergoing acute procedures. Stent thrombosis was observed in two patients receiving acute treatment for STEMI. Thus, cangrelor can be used in relation to PCI under acute circumstances with advantages in terms of clinical management. The benefits and risks, in terms of patient outcomes, should ideally be assessed in randomized trials.</p>","PeriodicalId":9494,"journal":{"name":"Cardiology Research and Practice","volume":"2023 ","pages":"3197512"},"PeriodicalIF":2.1,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10289876/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10074225","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Genetic Testing Enables the Diagnosis of Familial Hypercholesterolemia Underdiagnosed by Clinical Criteria: Analysis of Japanese Early-Onset Coronary Artery Disease Patients.","authors":"Hiroshi Miyama,&nbsp;Yoshinori Katsumata,&nbsp;Mizuki Momoi,&nbsp;Genki Ichihara,&nbsp;Taishi Fujisawa,&nbsp;Jin Endo,&nbsp;Takashi Kawakami,&nbsp;Masaharu Kataoka,&nbsp;Shinsuke Yuasa,&nbsp;Motoaki Sano,&nbsp;Kazuki Sato,&nbsp;Keiichi Fukuda","doi":"10.1155/2023/2236422","DOIUrl":"https://doi.org/10.1155/2023/2236422","url":null,"abstract":"<p><p>Definitive diagnosis of familial hypercholesterolemia (FH) is paramount for the risk management of patients and their relatives. The present study aimed to investigate the frequency of gene variants contributing to low-density lipoprotein cholesterol (LDL-C) metabolism and their clinical relevance in patients with early-onset coronary artery disease (EOCAD). Among 63 consecutive patients with EOCAD (men <55 years or women <65 years) who underwent percutaneous coronary intervention (PCI) from 2013 to 2019 at Keio University Hospital, 52 consented to participate in this retrospective study. Targeted sequencing of <i>LDLR</i>, <i>PCSK9</i>, <i>APOB</i>, and <i>LDLRAP1</i> was performed. Of the 52 patients enrolled (42 men; mean age: 50 ± 6 years), one (<i>LDLR</i>, c.1221_1222delCGinsT) harbored a pathogenic mutation, and one (<i>APOB</i>, c.10591A>G) harbored variants of uncertain significance. Both the patients harboring the variants were male, showing no history of diabetes mellitus or chronic kidney disease, no family history of EOCAD, and no physical findings of FH (i.e., tendon xanthomas or Achilles tendon thickening). Patients harboring the <i>LDLR</i> variant had three-vessel disease, were on a statin prescription at baseline, and had stable LDL-C levels; however, the case showed a poor response to the intensification of medication after PCI. Approximately 3.8% of patients with EOCAD harbored variants of gene related to LDL-C metabolism; there were no notable indicators in the patients' background or clinical course to diagnose FH. Given the difficulty in diagnosing FH based on clinical manifestations and family history, genetic testing could enable the identification of hidden risk factors and provide early warnings to their relatives.</p>","PeriodicalId":9494,"journal":{"name":"Cardiology Research and Practice","volume":"2023 ","pages":"2236422"},"PeriodicalIF":2.1,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10162874/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9430167","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-Term Outcomes of Bovine versus Porcine Mitral Valve Replacement: A Multicenter Analysis.","authors":"M Broadwin,&nbsp;N Ramkumar,&nbsp;D J Malenka,&nbsp;R D Quinn,&nbsp;C S Ross,&nbsp;F Hirashima,&nbsp;J D Klemperer,&nbsp;R S Kramer,&nbsp;G L Sardella,&nbsp;B Westbrook,&nbsp;A W Discipio,&nbsp;A Iribarne,&nbsp;M P Robich","doi":"10.1155/2023/2111843","DOIUrl":"https://doi.org/10.1155/2023/2111843","url":null,"abstract":"<p><strong>Introduction: </strong>Recent national guidelines recommending mitral valve replacement (MVR) for severe secondary mitral regurgitation have resulted in an increased utilization of mitral bioprosthesis. There is a paucity of data on how longitudinal clinical outcomes vary by prosthesis type. We examined long-term survival and risk of reoperation between patients having bovine vs. porcine MVR. <i>Study Design</i>. A retrospective analysis of MVR or MVR + coronary artery bypass graft (CABG) from 2001 to 2017 among seven hospitals reporting to a prospectively maintained clinical registry was conducted. The analytic cohort included 1,284 patients undergoing MVR (801 bovine and 483 porcine). Baseline comorbidities were balanced using 1 : 1 propensity score matching with 432 patients in each group. The primary end point was all-cause mortality. Secondary end points included in-hospital morbidity, 30-day mortality, length of stay, and risk of reoperation.</p><p><strong>Results: </strong>In the overall cohort, patients receiving porcine valves were more likely to have diabetes (19% bovine vs. 29% porcine; <i>p</i> < 0.001), COPD (20% bovine vs. 27% porcine; <i>p</i>=0.008), dialysis or creatinine >2 mg/dL (4% bovine vs. 7% porcine; <i>p</i>=0.03), and coronary artery disease (65% bovine vs. 77% porcine; <i>p</i> < 0.001). There was no difference in stroke, acute kidney injury, mediastinitis, pneumonia, length of stay, in-hospital morbidity, or 30-day mortality. In the overall cohort, there was a difference in long-term survival (porcine HR 1.17 (95% CI: 1.00-1.37; <i>p</i>=050)). However, there was no difference in reoperation (porcine HR 0.56 (95% CI: 0.23-1.32; <i>p</i>=0.185)). In the propensity-matched cohort, patients were matched on all baseline characteristics. There was no difference in postoperative complications or in-hospital morbidity and 30-day mortality. After 1 : 1 propensity score matching, there was no difference in long-term survival (porcine HR 0.97 (95% CI: 0.81-1.17; <i>p</i>=0.756)) or risk of reoperation (porcine HR 0.54 (95% CI: 0.20-1.47; <i>p</i>=0.225)).</p><p><strong>Conclusions: </strong>In this multicenter analysis of patients undergoing bioprosthetic MVR, there was no difference in perioperative complications and risk of reoperation of long-term survival after matching.</p>","PeriodicalId":9494,"journal":{"name":"Cardiology Research and Practice","volume":"2023 ","pages":"2111843"},"PeriodicalIF":2.1,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10328727/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9866276","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Outcomes of Combined Heart-Kidney Transplantation in Older Recipients.","authors":"Curry Sherard,&nbsp;Vineeth Sama,&nbsp;Jennie H Kwon,&nbsp;Khaled Shorbaji,&nbsp;Lauren V Huckaby,&nbsp;Brett A Welch,&nbsp;Chakradhari Inampudi,&nbsp;Ryan J Tedford,&nbsp;Arman Kilic","doi":"10.1155/2023/4528828","DOIUrl":"https://doi.org/10.1155/2023/4528828","url":null,"abstract":"<p><strong>Objectives: </strong>The upper limit of recipient age for combined heart-kidney transplantation (HKT) remains controversial. This study evaluated the outcomes of HKT in patients aged ≥65 years.</p><p><strong>Methods: </strong>The United Network of Organ Sharing (UNOS) was used to identify patients undergoing HKT from 2005 to 2021. Patients were stratified by age at transplantation: <65 and ≥ 65 years. The primary outcome was one-year mortality. Secondary outcomes included 90-day and 5-year mortality, postoperative new-onset dialysis, postoperative stroke, acute rejection prior to discharge, and rejection within one-year of HKT. Survival was compared using Kaplan-Meier analysis, and risk adjustment for mortality was performed using Cox proportional hazards modeling.</p><p><strong>Results: </strong>HKT in recipients aged ≥65 significantly increased from 5.6% of all recipients in 2005 to 23.7% in 2021 (<i>p</i>=0.002). Of 2,022 HKT patients in the study period, 372 (18.40%) were aged ≥65. Older recipients were more likely to be male and white, and fewer required dialysis prior to HKT. There were no differences between cohorts in unadjusted 90-day, 1-year, or 5-year survival in Kaplan-Meier analysis. These findings persisted after risk-adjustment, with an adjusted hazard for one-year mortality for age ≥65 of 0.91 (95% CI (0.63-1.29), <i>p</i>=0.572). As a continuous variable, increasing age was not associated with one-year mortality (HR 1.01 (95% CI (1.00-1.02), <i>p</i>=0.236) per year). Patients aged ≥65 more frequently required new-onset dialysis prior to discharge (11.56% vs. 7.82%, <i>p</i>=0.051). Stroke and rejection rates were comparable.</p><p><strong>Conclusion: </strong>Combined HKT is increasing in older recipients, and advanced age ≥65 should not preclude HKT.</p>","PeriodicalId":9494,"journal":{"name":"Cardiology Research and Practice","volume":"2023 ","pages":"4528828"},"PeriodicalIF":2.1,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10314816/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10121291","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Recombinant Adenovirus siRNA Knocking Down the Ndufs4 Gene Alleviates Myocardial Apoptosis Induced by Oxidative Stress Injury.","authors":"Beibei Wang,&nbsp;Jinsheng Zhang,&nbsp;Aijun Xu","doi":"10.1155/2023/8141129","DOIUrl":"https://doi.org/10.1155/2023/8141129","url":null,"abstract":"<p><p>Oxidative stress results in myocardial cell apoptosis and even life-threatening heart failure in myocardial ischemia-reperfusion injury. Specific blocking of the complex I could reduce cell apoptosis. Ndufs4 is a nuclear-encoded subunit of the mitochondrial complex I and participates in the electron transport chain. In this study, we designed and synthesized siRNA sequences knocking down the rat Ndufs4 gene, constructed recombinant adenovirus Ndufs4 siRNA (Ad-Ndufs4 siRNA), and primarily verified the role of Ndufs4 in oxidative stress injury. The results showed that the adenovirus infection rate was about 90%, and Ndufs4 mRNA and protein were decreased by 76.7% and 64.9%, respectively. Furthermore, the flow cytometry assay indicated that the cell apoptosis rate of the Ndufs4 siRNA group was significantly decreased as compared with the H₂O₂-treated group. In conclusion, we successfully constructed Ndufs4 siRNA recombinant adenovirus; furthermore, the downexpression of the Ndufs4 gene may alleviate H₂O₂-induced H9c2 cell apoptosis.</p>","PeriodicalId":9494,"journal":{"name":"Cardiology Research and Practice","volume":"2023 ","pages":"8141129"},"PeriodicalIF":2.1,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9897913/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9229248","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Retracted: The Long-Term Change of Arrhythmias after Transcatheter Closure of Perimembranous Ventricular Septal Defects.","authors":"Cardiology Research And Practice","doi":"10.1155/2023/9898161","DOIUrl":"https://doi.org/10.1155/2023/9898161","url":null,"abstract":"<p><p>[This retracts the article DOI: 10.1155/2021/1625915.].</p>","PeriodicalId":9494,"journal":{"name":"Cardiology Research and Practice","volume":"2023 ","pages":"9898161"},"PeriodicalIF":2.1,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10447158/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10061871","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}